A Study to Determine the Tolerability of Intranasal LMN-301

Summary

LMN-301 is to prevent infection by severe acute respiratory syndrome-corona virus (SARS-CoV-2) (the virus causing coronavirus disease of 2019 (COVID-19) in uninfected individuals. This study aims to assess whether the formulation will cause irritation when administered in the nose, and how long its protective effects will last. Thirty five healthy adult volunteers will participate in this study.

Timeline

Start

2023-10-06

Primary completion

2023-12-28

Completion

2024-04-03

Drugs

Indications